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Abstract: Topical diclofenac sodium (pennsaid) is a non-steroidal-anti- inflammatory drug 
that is used to manage the recurrent pain and symptoms of osteoarthritis of the knee. Pennsaid 
is applied topically, absorbed cutaneously and concentrates locally at the site of application. 
Tugwell et al. [54] has shown that pennsaid is as efficacious as oral diclofenac as a mode of 
pain relief without systemic effects. The most common side effect induced by pennsaid is the 
development of dry skin at the site of application. This is caused by dimethyl sulfoxide which 
is the vehicle used in the pennsaid formulation.  Dimethyl sulfoxide dissolves the natural oils 
in the skin causing dryness.  
 
Introduction to management issues in the treatment of osteoarthritis knee 
 
Osteoarthritis (OA) is a common condition that is associated with degeneration of joints. It is 
estimated that between 21 and 40 million people suffer from OA often involving at least one 
joint [1, 2, 3]. It is postulated that OA will become a global cause of disability by the year 
2020 [4] OA is a disorder of middle aged people, predominantly women and is a disease that 
progresses with advancing age [2,5,6]. Although it is common for radiographic evidence of 
OA to be present in individuals over 65 years [7], the severity of symptoms may correlate 
poorly with radiographic pathogenic alterations [8].  OA was once referred to as a ‘wear and 
tear’ disorder due to the progressive loss of articular cartilage from joints and underlying bone 
[8] which can lead to joint inflammation. Common sites for OA sites include the weight 
bearing joints such as the hip and knee [9]. These changes can be debilitating and painful [8]. 
In OA of the knee the characteristic symptoms which can be used to diagnose the condition 
include: joint pain in and around the knee joint site which may vary on severity from a 
constant dull ache to a sharp pain with motion; joint instability; crepitus (irregularity of 
opposing cartilage surfaces) on motion and limitation of range of motions leading to possible 
immobility; potential alterations to the gait; bony enlargement in affected joints; osteophytes 
on X ray, loss of ; function; morning stiffness lasting up to 30 minutes and age over 50 years 
[2, 5]. The onset of symptoms can be insidious. Pain may be worse during motion and can be 
alleviated by rest. These defining characteristics are required because pathogenic changes on 
X ray may occur without the patient demonstrating symptoms of pain. 
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In terms of the pathogenesis of OA of the knee, the central features include degenerative 
changes to the articular cartilage of joints, osteophyte (new bone) formation, progressive 
narrowing of the joint space between bone endings, subchondral sclerosis, chrondrocalcinosis 
and bone deformity [10]. OA develops when cartilage catabolism exceeds the process of 
cartilage synthesis. The proteolytic digestion of cartilage has also been associated with 
numerous cytokines; Interleukin-1 and tumour necrosis factor β [11].  It is proposed that 
insulin growth factor 1 and tissue growth factor β may be involved in cartilage synthesis and 
repair processes [12].These inflammatory changes are responsible for the destruction of the 
joint capsule. As the articular cartilage gradually erodes nociceptors become sensitized 
causing pain [13]. Pain can develop from the subchrondral bone, periosteum, joint capsule, 
synovial membrane, peri-articular muscles and ligaments and can result from the stretching of 
the adjacent periosteum, growth of osteophytes, impact of microfractures, intraosseous 
pressure and synovitis [14] . These changes can lead to limitations in movement and disability 
[15, 16].  
 
Pain is a complex sensory process which is related to specific tissue damage. In traumatic 
situations, inflammatory mediators such as prostaglandins, neuropeptides like substance P and 
calictonin-gene related peptide are released from blood vessels where they act as a stimulus 
and cause peripheral nociceptor C and Aδ fibers to depolarize. This leads to the transmission 
of signals (signal transduction) via the dorsal horn to the cerebrum. During inflammation, 
signal transmission to the dorsal horn does not require a stimulus therefore a hyperresponsive 
response exists. This hyperresponsive response can be controlled by Non Steroidal Anti-
Inflammatory Drugs (NSAIDs) [17].  
 
Management of OA and patient considerations 
Currently there is no cure for OA. Historically, pain management options include both non-
pharmacological and pharmacological approaches. Non-pharmacological management 
includes: dietary advice and exercise to encourage weight loss, social support, assistive 
devices for ambulation, appropriate footwear, occupational therapy, joint protection and 
devices to assist activities of daily living [2]. The efficacy of these approaches is limited 
because pain restricts mobility and willingness and ability to undertake any form of physical 
activity. Inactivity can hasten disability and exacerbate joint pain. For these reasons 
pharmacological treatment is viewed as the mainstay of treatment. Pharmacological 
approaches include the use of regular analgesics such as paracetamol to control pain. In 
patients with uncontrolled pain and symptom control the recent EULAR recommendations 
[18] suggest that NSAIDs can be used as part of pain management or patients with OA of the 
knee.  
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NSAIDs are a large range of drugs that includes; acetic acid derivates such as indomethacin 
and diclofenac, salicylates and commonly used propionic acid substitutes such as ibuprofen 
and naproxen. These oral forms of NSAIDs are commonly used for patients with moderate to 
severe OA related pain. However they are not without their drawbacks; NSAIDs are 
associated with the risk of gastrointestinal disturbance, gastrointestinal bleeding, gastric 
ulceration and renal disease complications and toxicity even at low doses [19]. The risk of 
gastrointestinal toxicity is increased in patients over the age of 65 years, those with a history 
of gastric ulcer, gastrointestinal bleeding particularly in patients who are prescribed multiple 
doses of NSAIDs [20]. In patients it is advisable to prescribe NSAIDs at the lowest possible 
dose possible and increase the dose as tolerance develops [21]. 
 
Cyclooxygenase -2-(COX-2) specific inhibitor such as celecoxib have also been used to 
manage the pain and symptom control in patients with moderate to severe pain associated 
with OA of the knee. Although studies show that COX -2 inhibitors are efficacious in the 
management of osteoarthritic symptoms [22, 23] can produce equivalent pain relief to the 
NSAID diclofenac [24, 25, 26], 27, 28] and are less likely to produce gastrointestinal 
disturbances but there is the increased risk of cardiovascular complications such as stroke and 
cardiac arrest. This problem led to the withdrawal of 2 widely used COX-2-specific 
inhibitors, rofecoxib and valdecoxib from the market. 
 
Topical NSAIDs are a safer option as the formulation allows the drug to be absorbed 
cutaneously in to the dermis, reaches its target site, the synovial membrane, peripheral nerves 
and soft tissues local to the site of application [29] and has low systemic availability [30]. The 
topical formulation improves tolerability with fewer reported fewer side effects, particularly 
reduced gastrointestinal side effects [31,32].. Numerous topical NSAIDs are now available of 
these, topical diclofenac is reported to be as efficacious as oral formulations without the risk 
of systemic side effects [33] .Additional reports indicate the added benefit of using topical 
diclofenac in terms of its ability to quickly relieve symptoms of morning stiffness, control 
pain and physical mobility [34, 35, 36]. Oral forms of diclofenac have been compared with 
paracetamol [37, 38, 39], leech therapy [40], enzymic anti-inflammatory compounds [41]. In 
all studies, diclofenac produced greater pain control and improved mobility in patients with 
OA. 
  
Since its development topical diclofenac has been used as an anti-inflammatory drug to 
alleviate the pain symptoms in patients with OA and researched in short-term, 2 week studies 
[42] and compared to ketoprofen [43] and placebo [44]. This time duration is too short to 
measure therapeutic effectiveness particularly as OA is a long-term chronic disease that 
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requires treatment over long periods of time. In order to assess the efficacy and safety of 
topical NSAIDS, studies should be conducted over periods longer than two weeks. Studies of 
short duration are unlikely to capture important long-term safety information which will be of 
importance for ongoing applications of gels, creams or sprays in chronic conditions.  
 
Drug Profile   
 
Diclofenac sodium is an arylacanoic acid and NSAID with analgesic properties. Consistent 
with other NSAIDs, diclofenac sodium interacts exerts its actions by inhibiting the 
cycloxygenase (COX) group of enzymes. Two forms of the COX enzyme exist; COX-1 is 
associated with gastric epithelium; COX-2 is responsible for prostaglandin synthesis. 
Inhibition of COX-2 reduces the production of inflammatory mediators such as 
prostaglandins [45, 46], substance P and interleukin-6. Diclofenac also alters G-protein 
mediated signal transduction pathways [29] and interacts with nociceceptors by exerting an 
enhanced effect on hyperalgic muscle [47].  
 
Diclofenac sodium is formulated as a lotion with the absorption enhancer dimethyl sulfoxide 
(DMSO). DMSO aids absorption of Diclofenac sodium particularly following repeated dosing 
[48, 49]. The absorption of diclofenac sodium can be altered by the integrity of the skin and 
impact of dehydration [50] DMSO is absorbed locally and distributed with plasma levels of 
0.48 µg/mL detected after 8 hours. The mean whole blood level of DMSO was 647±659.3 
ng/mL 6 hours after the last application. The mean elimination t½ was 8.4 hours [50]. 
 
Following a single application of diclofenac sodium the mean peak plasma diclofenac sodium 
concentration (Cmax) was 9.7±4.7 ng/ mL after 24 to 48 hours. After multiple applications, 4 
times per day for 84 days, the mean plasma level of diclofenac sodium as was 
8.95±9.17ng/mL [50]. In open label studies, patients administered 40 drops of diclofenac 
sodium to both knees for 8 days. Steady state was reached by day 6 and on day 8 and the 
mean plasma Cmax was 19.4 ng/mL with a mean Tmax of 4 hours. Values for the terminal t½ 
was 79.0 hours. 
 
Diclofenac is metabolized by cytochome P450 (CYP2C) and undergoes hydroxylation  during 
phase 1 to form hydroxylated derivatives which then undergo methylation followed by 
conjugation with glucuronic acid to form metabolites either as conjugates or sulfates during 
phase 2. The enhancer DMSO is either oxidized during phase 1 to form dimethyl sulfone or 
reduced to form dimethyl sulfide with no trace amounts detected following multiple dosing 
[49, 50]. 
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In terms of the drug elimination of diclofenac sodium, the plasma clearance is 263±56mL/ 
min. Up to 60-70% of metabolites are excreted in the urine [51] and 30% of metabolites are 
excreted in the faeces [50]. 
 
Efficacy studies 
 
Several studies have examined the effects of pennsaid on pain control and the associated 
symptoms of OA using the validated Western Ontario and MacMaster Universities 
Osteoarthritis Index (WOMAC) [52].. The WOMAC index examines pain, morning stiffness 
and physical function using a questionnaire in patients with OA of the knee.  The 
questionnaire has 24 questions (5 pain related; 17 related to physical function; 2 on morning 
stiffness), patients respond to each question using a likert scale of mild to extreme measured 
on a scale of 1-5. The WOMAC questionnaire has a reported cronbach’s alpha of 0.93 and a 
test-retest reliability of 0.86 [52]. Four randomized controlled trials (RCTS) examined the 
efficacy of topical diclofenac compared to either a vehicle containing the absorption enhancer 
DMSO or oral formulations of diclofenac  [33, 34, 35, 36]. See Table 1.  
 
The efficacy of topical diclofenac was assessed in patients aged 40-85 years, predominantly 
female, with a history of OA of the knee defined by one key characteristic, e.g. radiological 
evidence of abrasion, deterioration of articular cartilage, osteophyte formation at the surface 
of the knee or flare of pain after removal of analgesic therapy. Patients with evidence of OA 
knee were randomized to topical diclofenac or DMSO for periods of 4-12 weeks [34, 35, 36]. 
Salient findings indicate that patients receiving topical diclofenac reported significant pain 
relief, improved physical function and morning stiffness compared to patients administering a 
vehicle control solution [34., 35, 36]. In the longest duration study (12 weeks) reported  
improvements in pain control (p=0.01), physical function (p= 0.02), morning stiffness 
(p=0.05) [36] Additional parameters pain on walking was favourably assessed by patients 
(p=0.04) and patient global assessment (p=0.03).  Patient global assessment (PGA) is based 
on OMERACT-OARSI responder criteria [53]. A responder is defined as a patient with >50% 
improvement in pain or function that was graded as ≥ 20% of the scale or ≥ 20% 
improvement in at least two areas; pain and physical function or a PGA that was ≥ 10% of the 
scale. Baer et al., [34] reported PGA of (-1.3 vs 0.7, p=0.001) wheras Bookman et al. [35]  
reported a PGA ( p=0.039). 
 
In all three studies, the main reported side effect of topical diclofenac was dryness of the skin 
around the site of application. This effect was reported in 36% of patients [35], 39% of 
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patients [34] and 41% of patients [36]. In all studies this side effect led to less than 6% of 
patients discontinuing treatment (34, 35, 36].  In the study by Roth et al., [36]  patients 
complained that the solution used in topical diclofenac and in control caused halitosis or 
garlic breath. This is due to the metabolism of DMSO to dimethyl sulfide and dimethyl 
sulfone [54 ].   
 
It was also reported that 1 patient treated with topical diclofenac showed minor elevations in 
serum alanine aminotransferase and aspartate aminotransferase. [35]  This elevation was 1.2 
times the upper limit of normal when both levels were elevated. This effect was not repeated 
in the DMSO only group.  More recently, Tugwell et al., [33] reported elevated serum alanine 
aminotransferase and aspartate aminotransferase in 2-5% of patients receiving topical 
diclofenac and 10%-17% of patients administering oral diclofenac [ 33]. 
 
Tugwell et al. [33] also found no clinically significant differences between topical diclofenac 
compared to an oral diclofenac formulation. In both drug groups, patients developed 
symptoms of dyspepsia, diarrhea, nausea, flatulence and abdominal pain. However, these 
gastric symptoms were more common in patients receiving oral diclofenac. Up to patients 
(27%) administering topical diclofenac reported symptoms of minor skin irritation or pruritis. 
The development of drug-induced pruritis concurs with reported studies [34, 35, 36]. In 
addition, some patients developed a vesiculobullous rash, of these 5% discontinued their 
treatment [33] which concur with published findings [35]. Following discontinuation of 
treatment, the symptoms of rash resolved. 
 
Following an assessment of RCTs it was reported that pennsaid is a safe and effective 
alternative NSAID for patients with OA knee [33]. The main drawback of treatment is the 
development of dry skin.  
 
Safety and tolerability  
Historically NSAIDs have been associated with serious gastrointestinal and renal disorders 
such as peptic ulceration, ulcer perforation, gastrointestinal bleeding, anaemia [33], acute 
renal failure and small bowel injury [55]. The use of topical diclofenac markedly reduces the 
incidence of these adverse effects due to systematic exposure without loss of efficacy. [56]. 
Dyspepsia is a common side effect of NSAIDs, should patients experience symptoms of 
dyspepsia, they should be instructed to notify the prescriber immediately. Prescribers need to 
be pharmacovigliant to respond quickly to gastric symptoms as gastrointestinal bleeding or 
ulceration can occur quickly and in such conditions pennsaid should be discontinued. Patients 
need to be educated about the need for follow-up if gastric symptoms occur. In patients with a 
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history of peptic ulceration, inflammatory conditions of the bowel such as Crohn’s disease or 
ulcerative colitis, pennsaid should be prescribed under close supervision. Furthermore, in 
older people, pennsaid should be prescribed under close supervision due to increased 
susceptibility to adverse drug reactions and risk of lower esophageal ulceration and bleeding 
[50]. 
 
The long-term safety of pennsaid is unknown, because of this, the drug should be used as a 
treatment regimen for OA knee for no longer than three months either as a continuous or 
intermittent therapy. Pennsaid should not be prescribed for lactating women due to deficient 
safety data. In addition to this, pennsaid should not be administered concurrently with other 
NSAIDs because of the risk of additive side effects or applied directly to open wounds, 
abraded or infected skin [50]. Due to the risk of anaphylaxis, pennsaid should not be used in 
patients with a history of asthma, urticaria/ angioedema, or nasal polyps.   
 
Pennsaid causes a dose-dependent reduction in prostaglandins which can lead to overt renal 
decompensation. As a result of this, patients with a history of impaired renal function, heart 
failure particularly older people may be susceptible to renal toxicity.  If these types of patients 
are prescribed Pennsaid, they need to be monitored carefully [50] . 
 
DMSO is a relatively safe compound with no reported nephrotoxicity or mutagenicity. 
However, DMSO is metabolized to form dimethyl sulfide which is a volatile gas that can 
either be excreted via the skin or through the breath and cause a garlic-like odour/ taste which 
can be unpleasant for patients [54]. DMSO dissolves the fat cells in skin causing dryness of 
the skin which can be unpleasant for patients. In recent trials, pennsaid caused skin irritation 
in up to 39% of patients this is rather high and can possibly led to discontinuation of treatment 
[34, 35, 36].  
 
There is a paucity of evidence that has examined patient’s views on the treatment of pennsaid. 
Patient considerations tend to be reflected in accounts of RCTs with regard to symptoms 
encountered or data on drop out from studies, e.g. lack of effect from drugs used [35]. It is 
important that authors report patient considerations, albeit, the short duration of studies may 
be a prohibiting factor in such exploration.     
 
Conclusions  
 
Pennsaid is a topical NSAID which has been shown to be an effective and safe alternative for 
patients with OA of the knee. Four RCTS have demonstrated that pennsaid can significantly 
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improve WOMAC criteria; pain control, physical function and morning stiffness as well as 
improving OMERACT-OARSI responder criteria patient global assessment. Tugwell et al., 
[332004) found that pennsaid produced equivalent efficacy to oral diclofenac in patients with 
OA knee. In the remaining three RCTS, pennsaid was more efficacious then control in terms 
of WOMAC criteria. The most common side effect specific to pennsaid was the development 
of dry skin; in the majority of patients this was not severe enough to cause patients to 
discontinue therapy. In a small number of patients, gastric symptoms and elevated liver 
enzymes were reported however these changes were not significant enough to discontinue 
therapy. Data on patient experiences of using pennsaid are limited to the reporting of 
symptoms. Additional studies are needed to explore in depth how patients respond and 
potentially benefit from using pennsaid. Overall the data from RCTs indicate support the use 
of pennsaid as a topical NSAID to be used continuously in patients with OA of the knee for 
periods of up to 12 weeks. 
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Table 1. Characteristics of RCTs and meta-analyses involving OA of the knee 
 
PARAMETERS BAER BOOKMAN ROTH  TUGWELL 
Study RCT RCT RCT RCT 
Duration 6 weeks 4 weeks 12weeks 12 weeks 
 13 
Sample 216 248 326 622 
Drug 1.5% 
dic. Na 
1.5% dic Na 1.5% dic 
Na 
1.5% dic Na 
versus oral 
dic. 
Pain relief 
reduction 
-5.2vs 
3.3. p= 
0.002 
-3.9 vs -2.5 
p=0.023 
-7.1 vs -
5.6. 
p=0.02 
44% dic na  
versus 49 % 
oral dic. 
Physical function 
Improvement 
-13.4vs -
6.9 p= 
0.01 
-11.6vs -8.4, 
p=0.023 
-18.5 vs -
14.3 
p=0.04  
39% dic na  
versus 46 % 
oral dic.3 
Stiffness 
Improvement 
-1.8 vs -
0.9 
p=0.002 
-1.5 vs -0.7 
p=0.003 
-2.3 vs -
1.6 
p=0.02 
39% dic na  
versus 45 % 
oral dic. 
PGA 
improvement 
-1.3 vs -
0.7  
p=0.001 
-6.7vs 7.8 
p0.039 
-1.5 vs -
1.2 
p=0.06 
43% dic na  
versus 49 % 
oral dic. 
Side effects Dry skin 
in 39% 
of cases 
Dry skin in 
36% of cases 
Dry skin 
in 36.6% 
of cases 
Dry skin in 
27% of 1.5% 
Dic Na cases 
 
Dic Na refers to diclofenac sodium solution. 
Oral dic. Refers to 50 mg oral diclofenac capsules  
Pain, physical function and stiffness were assessed using the WOMAC  LK3.1 OA index 
criteria measured on a 5 –point  likert scale where 0 indicates none, 1 indicates mild, 2 
indicates moderate, 3 indicates severe and 4 indicates extreme. 
 
PGA refers to physical general assessment measured using a visual analogue scale from   very 
good (0) to extreme (4). 
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